Treatment of hepatitis C infection in patients with renal disease

Jorge M. Diego; David Roth

doi:10.1097/00041552-199809000-00012

Treatment of hepatitis C infection in patients with renal disease

Jorge M. Diego, David Roth

Medicine

Research output: Contribution to journal › Review article

19 Scopus citations

Abstract

Hepatitis C virus infects 20-40% of the end-stage renal disease population, and has been associated with essential mixed cryoglobulinemia and several forms of immune-complex glomerulonephritis. Overall, treatment with interferon alpha has been disappointing, although certain situations may benefit from dosing regimens that differ in the amount of drug and duration of treatment from the conventional interferon doses currently recommended for non-renal patients.

Original language	English (US)
Pages (from-to)	557-562
Number of pages	6
Journal	Current Opinion in Nephrology and Hypertension
Volume	7
Issue number	5
DOIs	https://doi.org/10.1097/00041552-199809000-00012
State	Published - Oct 28 1998

ASJC Scopus subject areas

Internal Medicine
Nephrology

Access to Document

10.1097/00041552-199809000-00012

Fingerprint Dive into the research topics of 'Treatment of hepatitis C infection in patients with renal disease'. Together they form a unique fingerprint.

Cite this

Diego, J. M., & Roth, D. (1998). Treatment of hepatitis C infection in patients with renal disease. Current Opinion in Nephrology and Hypertension, 7(5), 557-562. https://doi.org/10.1097/00041552-199809000-00012

@article{c5e61bf9e73345dc9c01afa29951cd51,

title = "Treatment of hepatitis C infection in patients with renal disease",

abstract = "Hepatitis C virus infects 20-40% of the end-stage renal disease population, and has been associated with essential mixed cryoglobulinemia and several forms of immune-complex glomerulonephritis. Overall, treatment with interferon alpha has been disappointing, although certain situations may benefit from dosing regimens that differ in the amount of drug and duration of treatment from the conventional interferon doses currently recommended for non-renal patients.",

author = "Diego, {Jorge M.} and David Roth",

year = "1998",

month = oct,

day = "28",

doi = "10.1097/00041552-199809000-00012",

language = "English (US)",

volume = "7",

pages = "557--562",

journal = "Current Opinion in Nephrology and Hypertension",

issn = "1062-4821",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Treatment of hepatitis C infection in patients with renal disease

AU - Diego, Jorge M.

AU - Roth, David

PY - 1998/10/28

Y1 - 1998/10/28

N2 - Hepatitis C virus infects 20-40% of the end-stage renal disease population, and has been associated with essential mixed cryoglobulinemia and several forms of immune-complex glomerulonephritis. Overall, treatment with interferon alpha has been disappointing, although certain situations may benefit from dosing regimens that differ in the amount of drug and duration of treatment from the conventional interferon doses currently recommended for non-renal patients.

AB - Hepatitis C virus infects 20-40% of the end-stage renal disease population, and has been associated with essential mixed cryoglobulinemia and several forms of immune-complex glomerulonephritis. Overall, treatment with interferon alpha has been disappointing, although certain situations may benefit from dosing regimens that differ in the amount of drug and duration of treatment from the conventional interferon doses currently recommended for non-renal patients.

UR - http://www.scopus.com/inward/record.url?scp=0031686869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031686869&partnerID=8YFLogxK

U2 - 10.1097/00041552-199809000-00012

DO - 10.1097/00041552-199809000-00012

M3 - Review article

C2 - 9818204

AN - SCOPUS:0031686869

VL - 7

SP - 557

EP - 562

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 5

ER -